Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer

4. august 2026 opdateret af: Tianjin Medical University Second Hospital

A Prospective, Multicenter, Randomized Controlled Study of Disitamab Vedotin Plus Toripalimab With or Without Pelvic Lymph Node Dissection for Bladder-Sparing Treatment in Patients With cT2-3N0M0 Bladder Urothelial Carcinoma

This is a prospective, multicenter, randomized controlled superiority study designed to evaluate whether the addition of pelvic lymph node dissection improves bladder-intact event-free survival in patients with cT2-3N0M0 bladder urothelial carcinoma receiving bladder-sparing treatment. Eligible patients with HER2 expression of IHC 2+ or higher who decline radical cystectomy will be randomized 1:1 to receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab with or without standardized pelvic lymph node dissection. The primary endpoint is the 2-year bladder-intact event-free survival rate. Secondary endpoints include clinical complete response, partial response, disease progression, overall survival, quality of life, safety, treatment cost, and exploratory biomarker analyses.

Studieoversigt

Detaljeret beskrivelse

Muscle-invasive bladder cancer is commonly treated with radical cystectomy; however, bladder-sparing strategies are needed for selected patients who decline cystectomy. This study evaluates a bladder-sparing strategy based on maximal transurethral resection of bladder tumor, disitamab vedotin plus toripalimab, and the addition of standardized pelvic lymph node dissection.

Participants will be randomized to receive disitamab vedotin plus toripalimab with or without pelvic lymph node dissection after maximal transurethral resection of bladder tumor. Tumor response will be assessed by imaging, cystoscopy or transurethral resection/biopsy when clinically indicated, and urine cytology. Participants who meet bladder-sparing criteria will enter bladder-intact follow-up according to the protocol. Safety, survival, quality of life, treatment cost, and exploratory biomarkers will also be evaluated.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

114

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300211
        • The Second Hospital of Tianjin Medical University
        • Kontakt:
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Male or female participants aged 18 years or older.
  2. Histologically confirmed bladder urothelial carcinoma.
  3. Clinical stage cT2-3N0M0 according to the AJCC 8th edition TNM staging system.
  4. HER2 expression of IHC 2+ or higher.
  5. Participants who decline radical cystectomy as assessed by the investigator.
  6. Adequate organ function as defined in the study protocol.
  7. Ability to understand and willingness to sign written informed consent.

Exclusion Criteria:

  1. Known allergy or hypersensitivity to disitamab vedotin, toripalimab, their excipients, or other monoclonal antibodies.
  2. Prior radiotherapy for bladder cancer.
  3. Prior anticancer treatment that may affect efficacy assessment, as defined in the study protocol.
  4. Pregnant or breastfeeding women.
  5. Any serious uncontrolled disease or medical condition that, in the investigator's judgment, would make participation inappropriate.
  6. Participation in another interventional clinical trial that may interfere with this study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Disitamab Vedotin Plus Toripalimab With Pelvic Lymph Node Dissection
Participants will receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab and standardized pelvic lymph node dissection.
Disitamab vedotin will be administered in combination with toripalimab according to the study protocol.
Toripalimab will be administered in combination with disitamab vedotin according to the study protocol.
Maximal transurethral resection of bladder tumor will be performed as part of the bladder-sparing treatment strategy.
Standardized pelvic lymph node dissection will be performed in participants assigned to the PLND arm.
Aktiv komparator: Disitamab Vedotin Plus Toripalimab Without Pelvic Lymph Node Dissection
Participants will receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab without planned pelvic lymph node dissection.
Disitamab vedotin will be administered in combination with toripalimab according to the study protocol.
Toripalimab will be administered in combination with disitamab vedotin according to the study protocol.
Maximal transurethral resection of bladder tumor will be performed as part of the bladder-sparing treatment strategy.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
2-year Bladder-intact Event-free Survival Rate
Tidsramme: 24 months after randomization
The proportion of participants who remain alive with an intact bladder and without muscle-invasive bladder cancer recurrence, regional lymph node recurrence, distant metastasis, radical cystectomy, or bladder cancer-related death at 24 months after randomization.
24 months after randomization

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinical Complete Response Rate
Tidsramme: After completion of induction treatment, up to 12 weeks
The proportion of participants who achieve clinical complete response, defined as no visible tumor on imaging, no evidence of malignancy on cystoscopy or TURBT/biopsy when clinically indicated, and negative urine cytology. For participants undergoing pelvic lymph node dissection, no lymph node metastasis is required.
After completion of induction treatment, up to 12 weeks
Partial Response Rate
Tidsramme: After completion of induction treatment, up to 12 weeks
The proportion of participants with non-muscle-invasive disease, including Ta, T1, or carcinoma in situ, confirmed by urine cytology or pathological biopsy, with no evidence of locally advanced or metastatic disease on imaging.
After completion of induction treatment, up to 12 weeks
Disease Progression Rate
Tidsramme: Up to 24 months after randomization
The proportion of participants with disease progression, defined as muscle-invasive bladder cancer confirmed by pathological biopsy, locally advanced disease, regional lymph node recurrence, distant metastasis, or bladder cancer-related death.
Up to 24 months after randomization
Overall Survival
Tidsramme: Up to 60 months after randomization
Overall survival is defined as the time from randomization to death from any cause.
Up to 60 months after randomization
Incidence and Severity of Adverse Events
Tidsramme: From the first dose through 30 days after the last dose, up to approximately 19 months
The incidence, severity, and relationship to study treatment of adverse events will be assessed according to the Common Terminology Criteria for Adverse Events.
From the first dose through 30 days after the last dose, up to approximately 19 months
Quality of Life Score
Tidsramme: Baseline to 24 months after randomization
Quality of life will be assessed using the EORTC QLQ-C30 questionnaire according to the study protocol.
Baseline to 24 months after randomization
Total Treatment Cost
Tidsramme: From randomization to the end of follow-up, up to 60 months
Total treatment cost will be calculated from randomization to the final follow-up according to the study protocol.
From randomization to the end of follow-up, up to 60 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
2-Year Bladder-Intact Event-Free Survival Rate by Baseline HER2 IHC Category
Tidsramme: 24 months after randomization
Pretreatment tumor HER2 expression will be assessed by immunohistochemistry and categorized as IHC 2+ or IHC 3+. The percentage of participants meeting the 2-year bladder-intact event-free survival definition will be estimated separately for each HER2 IHC category. Bladder-intact event-free survival is defined as being alive with an intact bladder and without muscle-invasive bladder cancer recurrence, regional lymph node recurrence, distant metastasis, radical cystectomy, or bladder cancer-related death. The unit of measure is percentage of participants.
24 months after randomization

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. august 2026

Primær færdiggørelse (Anslået)

20. juni 2029

Studieafslutning (Anslået)

20. juni 2031

Datoer for studieregistrering

Først indsendt

27. juni 2026

Først indsendt, der opfyldte QC-kriterier

4. august 2026

Først opslået (Faktiske)

10. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. august 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

The plan for sharing de-identified individual participant data has not been determined and will be decided after completion of the study, subject to approval by the sponsor, principal investigator, and ethics committee.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner